medigraphic.com
ISSN 1405-8871 (Print)

2021, Number 4

<< Back Next >>

Aten Fam 2021; 28 (4)

SARS-CoV-2 Vaccines Efficacy in Mexico and the World

Camarillo NVM, Pérez LD, López RE

Language: Spanish
References: 24
Page: 291-295
PDF size: 222.16 Kb.


ABSTRACT

The current phase of the pandemic in different regions of the world is complex, a high community transmission of variants adapted to infect more susceptible people, combined with the increasing availability of different vaccines against COVID-19, leads to the need to review basic aspects of the vaccines such as their efficacy, dosage and main side effects, among other aspects of interest. It is also important to contrast the COVID-19 vaccines currently in use. In this review, an intentional search was carried out by type of vaccine applied and manufacturing laboratory in Mexico. Clinical trials and different secondary sources in PubMed and academic search engines were selected. The primary search variable was vaccine efficacy and its safety profile; secondary variables were viral platforms, dose and site of application. At the time of searching for this information, there were 287 vaccines against COVID-19 in development, five different vaccines had been licensed in our country; one based on mrna technology (Pfizer), four based on viral vectors (AstraZeneca, CanSino, Sputnik V, Jennsen) and one based on inactivated virus (Sinovac). With the exception of CanSino which efficacy data are not available, the performance in the other licensed vaccines offers an excellent safety profile and protection against COVID- 19. Efforts to improve vaccination coverage in the Mexican population should be reinforced.


REFERENCES

  1. WHO. COVID-19 vaccine tracker and landscape [Internet]. [Citado 2021 Jun 10]. Disponible en: https://www.who.int/publications/m/item/draftlandscape- of-covid-19-candidate-vaccines

  2. Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020 Apr;580(7805):576- 577.

  3. Lu R, Zhao X, Li J y col. Caracterización genómica y epidemiología del nuevo coronavirus de 2019: implicaciones de los orígenes del virus y la unión al receptor. Lancet. 2020; 395 : 565‐574.

  4. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA takes action to help facilitate timely development of safe, effective COVID- 19 vaccines [Internet]. [Citado 2021 Jun 10]. Disponible en: https://www.fda.gov/news-events/ press-announcements/coronavirus-covid-19-update- fda-takes-action-help-facilitate-timelydevelopment- safeeffective-covid

  5. Xu J, Jia W, Wang P, Zhang S, Shi X, Wang X, Zhang L. Antibodies and vaccines against Middle East respiratory syndrome coronavirus. Emerg Microbes Infect. 2019;8(1):841-856.

  6. Saunders KO, Lee E, Parks R, et al. SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys. Preprint. bioRxiv. 2021;2021.02.17.431492.

  7. Murphy K, Casey W. Janeway´s inmmunobiology. 9th ed. New York: Garland Science; 2017. p. 729- 741.

  8. Wang J, Peng Y, Xu H, Cui Z, Williams RO 3rd. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech. 2020 Aug 5;21(6):225.

  9. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260-1263.

  10. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. mRNA- 1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020 Dec 17;383(25):2427- 2438.

  11. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020 Dec 30:NEJMoa2035389.

  12. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. mRNA-1273 Study Group. Durability of Responses after SARSCoV- 2 mRNA-1273 Vaccination. N Engl J Med. 2021 Jan 7;384(1):80-82.

  13. Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020;383(25):2439-2450.

  14. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615.

  15. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111.

  16. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 2:S0140- 6736(21)00234-8.

  17. Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021 Jan 14;12(1):372.

  18. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021 Jan 13:NEJMoa2034201.

  19. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX,et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun 13;395(10240):1845-1854.

  20. Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021 May;21(5):637-646.

  21. Rab S, Afjal, Javaid M, Haleem A, Vaishya R. Una actualización sobre el desarrollo de una vacuna global para el coronavirus. Diabetes Metab Syndr. 2020 noviembre-diciembre; 14 (6): 2053-2055.

  22. Gao Q, Bao L, Mao H, Wang L, Qin C. Desarrollo de una vacuna candidata inactivada para el SARSCoV- 2. Ciencias. 2020; 369 : 77-81.

  23. Zhang Y, Zeng G, Pan H, Li C, Kan B, Hu Y, et al. Inmunogenicidad y seguridad de una vacuna inactivada contra el SARS-CoV-2 en adultos sanos de 18 a 59 años: informe del ensayo clínico de fase 2 aleatorizado, doble ciego y controlado con placebo. medRxiv [Preprint]. (2020).

  24. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020 Nov 14;396(10262):1595-1606.




2020     |     www.medigraphic.com